{"id":20530,"date":"2025-03-21T19:20:16","date_gmt":"2025-03-21T12:20:16","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=20530"},"modified":"2025-03-21T19:20:16","modified_gmt":"2025-03-21T12:20:16","slug":"syneron-bio-announces-strategic-collaboration-with-astrazeneca","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=20530","title":{"rendered":"Syneron Bio Announces Strategic Collaboration with AstraZeneca"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 21, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader\u00a0AstraZeneca\u00a0to develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases.\u00a0Under this collaboration,\u00a0AstraZeneca will gain access to\u00a0Syneron Bio&#8217;s innovative Synova\u2122 platform, an intelligent\u00a0and high-throughput macrocyclic peptide drug research and development platform, designed to support the advancements of research programmes exploring possible future treatments of chronic diseases,\u00a0including rare, autoimmune,\u00a0and metabolic disease.<\/p>\n<p>Under the terms of the agreements, AstraZeneca will provide upfront payments and potential near-term milestone payments totaling <span class=\"xn-money\">$75 million<\/span> and up to <span class=\"xn-money\">$3.4 billion<\/span> in additional development and commercial milestones. In addition, tiered royalties will be paid based on global sales. AstraZeneca will also make an equity investment .\u00a0As a result of this collaboration, Syneron Bio plans to expand its Beijing R&amp;D center.<\/p>\n<p>Dr. <span class=\"xn-person\">Frank Zhang<\/span>, Founder and CEO of Syneron Bio, commented, &#8220;We are honored to partner with AstraZeneca. Interest in our Synova\u2122 platform is incredibly\u00a0inspiring and driven by the promising research and results we have already delivered. In the face of growing challenges posed by\u00a0chronic diseases such as autoimmune and metabolic disorders, this collaboration underscores our commitment to advancing drug development.<\/p>\n<p><b>About Syneron Bio:<\/b><\/p>\n<p>Syneron Bio is a biotech company dedicated to the development of next-generation macrocyclic\u00a0peptide therapeutics, employing its proprietary <b>Synova\u2122<\/b>\u00a0platform. The company has built a robust pipeline targeting oncology and chronic diseases. With a team experienced in drug development and data science, Syneron Bio has completed multiple rounds of equity financing in less than three years, backed by multiple\u00a0leading\u00a0venture capital funds.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">BEIJING<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 21, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader\u00a0AstraZeneca\u00a0to develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases.\u00a0Under this collaboration,\u00a0AstraZeneca will gain access to\u00a0Syneron Bio&#8217;s innovative Synova\u2122 platform, an intelligent\u00a0and high-throughput macrocyclic peptide drug research and development platform, designed to support the advancements of research programmes exploring possible future treatments of chronic diseases,\u00a0including rare, autoimmune,\u00a0and metabolic disease.<\/p>\n<p>Under the terms of the agreements, AstraZeneca will provide upfront payments and potential near-term milestone payments totaling <span class=\"xn-money\">$75 million<\/span> and up to <span class=\"xn-money\">$3.4 billion<\/span> in additional development and commercial milestones. In addition, tiered royalties will be paid based on global sales. AstraZeneca will also make an equity investment .\u00a0As a result of this collaboration, Syneron Bio plans to expand its Beijing R&amp;D center.<\/p>\n<p>Dr. <span class=\"xn-person\">Frank Zhang<\/span>, Founder and CEO of Syneron Bio, commented, &#8220;We are honored to partner with AstraZeneca. Interest in our Synova\u2122 platform is incredibly\u00a0inspiring and driven by the promising research and results we have already delivered. In the face of growing challenges posed by\u00a0chronic diseases such as autoimmune and metabolic disorders, this collaboration underscores our commitment to advancing drug development.<\/p>\n<p><b>About Syneron Bio:<\/b><\/p>\n<p>Syneron Bio is a biotech company dedicated to the development of next-generation macrocyclic\u00a0peptide therapeutics, employing its proprietary <b>Synova\u2122<\/b>\u00a0platform. The company has built a robust pipeline targeting oncology and chronic diseases. With a team experienced in drug development and data science, Syneron Bio has completed multiple rounds of equity financing in less than three years, backed by multiple\u00a0leading\u00a0venture capital funds.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-20530","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/20530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20530"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/20530\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}